A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.
暂无分享，去创建一个
D. Tu | M. Moore | J. Zalcberg | J. Simes | L. Siu | J. Ringash | D. Jonker | C. O'Callaghan | T. Price | J. Shapiro | N. Mittmann | S. Virk | L. Zhu | I. Walters | P. Smith | R. Gill | N. Magoski | D. Nomikos | M. Savoie | F. El-Tahche